Posts

FDA investigates tumor reports linked to Zolgensma

on
The FDA is investigating reports of tumors in patients previously treated with Novartis’ Zolgensma, a gene therapy for spinal muscular atrophy (SMA). Novartis reported nine tumor cases among patients treated since Zolgensma’s 2019 approval. Tumors were reported in the kidneys, nervous system, and areas in or around the spine. Three cases involved the cancer-associated gene GLI1. In two, testing found that DNA from the therapy’s AAV viral vector had integrated into the patient’s genome near or within GLI1. The third case is still being investigated. The FDA says the potential risk also applies to Itvisma, another Novartis SMA therapy using the same vector and construct. It is assessing whether regulatory action is needed. The FDA says the benefits of Zolgensma and Itvisma continue to outweigh their potential risks for approved uses while the review proceeds. The reports do not mean that every tumor was caused by treatment. Sources: FDA opens safety probe into Novartis' Z...

argenx to acquire Unnatural Products for up to $1.15 billion

on

Hims & Hers and Eli Lilly agree to offer branded weight-loss drugs

on

Novartis’s Lp(a) drug sharply lowered the biomarker but did not prevent cardiovascular events

on

J&J’s oral Icotyde shows promising PsA results, but higher dose misses statistical mark

on

Zura Bio drops HS program after Phase 2 trial miss

on

CRISPR reports encouraging early zugo-cel responses across autoimmune disease cohorts

on

Vir’s hepatitis D drug combination succeeds in first pivotal study

on

Network Bio and Duke team up to build AI disease models

on

Moderna raises growth outlook as vaccine sales and newer products gain momentum

on

Ziltivekimab lowered inflammation markers, but ZEUS found no cardiovascular-event benefit

on

Moderna’s COVID vaccine sales power a Q3 revenue beat

on

Chai Discovery adds Roche to its AI drug-discovery partnerships

on